Dr. Reddy’s gains on completing acquisition of product portfolio from TEVA

04 Aug 2016 Evaluate

Dr. Reddy’s Laboratories is currently trading at Rs. 2952.90, up by 10.95 points or 0.37% from its previous closing of Rs. 2941.95 on the BSE.

The scrip opened at Rs. 2969.90 and has touched a high and low of Rs. 2969.90 and Rs. 2952.90 respectively. So far 2,243 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.

Last one week high and low of the scrip stood at Rs. 3003.00 and Rs. 2925.10 respectively. The current market cap of the company is Rs. 48,821.57 crore.

The promoters holding in the company stood at 26.37%, while Institutions and Non-Institutions held 41.16% and 15.64% respectively.

Dr. Reddy’s Laboratories has successfully completed the previously announced acquisition of eight Abbreviated New Drug Applications (ANDAs) in the US from Teva Pharmaceutical Industries (TEVA) and an affiliate of Allergan plc. The acquired portfolio consists of products that are being divested by TEVA as a precondition to its closing of the acquisition of Allergan’s generics business.

The portfolio being acquired is a mix of six ANDAs pending approval, one approved ANDA and one ANDA with tentative approval, and comprises complex generic products across diverse dosage forms. The combined sales of the branded versions of the products in the US are approximately $3.5 billion MAT for the most recent twelve months ending in June 2016 according to IMS Health.

The products include Buprenorphine HCI/Naloxone HCI Sublingual Film (generic equivalent to Suboxone sublingual film), Ethinyl estradiol/Ethonogestrel Vaginal Ring (generic equivalent to NuvaRing), Ezetimibe/Simvastatin Tablets (generic equivalent to Vytorin), Metformin HCI/Saxagliptin ER Tablets (generic equivalent to Kombiglyze XR), Tobramycin Inhalation Solution (generic equivalent to Tobi), Phentermine HCI/Topiramate ER Capsules (generic equivalent to Qsymia), Imiquimod Topical Cream (generic equivalent to Zyclara 3.75% Cream), and Ramelteon Tablets (generic equivalent to Rozerem).

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Dr. Reddys Lab Share Price

1209.45 1.95 (0.16%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×